吉西他滨联合奥沙利铂治疗晚期原发性肝癌患者的疗效和安全性研究

Study of the efficacy and safety of GEMOX regimen for the patients with advanced primary liver cancer

目的探究吉西他滨(GEM)联合奥沙利铂(OXA)治疗晚期原发性肝癌患者的疗效与安全性。方法将2010年1月至2013年10月收治的60例晚期原发性肝癌患者,按照随机数字表法,分为观察组与对照组,每组均30例,分别采用吉西他滨联合奥沙利铂治疗与单纯采用吉西他滨治疗,对比两组患者的临床疗效与安全性。结果经各自治疗后,观察组的局部控制率为63.33%,显著高于对照组的33.33%,差异具有显著性(χ2=4.271,P=0.039);血小板与中性粒细胞减少是两组患者的主要毒副作用,且在不同的毒副作用发生率对比,差异无统计学意义(P>0.05)。结论吉西他滨联合奥沙利铂治疗晚期原发性肝癌患者,能够有效改善临床疗效,提高局部控制率,且不增加发生毒副作用的风险,值得临床推广应用。

Objective To investigate the efficacy and safety of gemcitabine （GEM） combined with oxaliplatin （OX） in the treatment of the patients with advanced primary liver cancer. Methods A total of 60 patients with advanced primary liver cancer from January 2010 to October 2013 in Taishan Peopleg Hospital were divided into 30 cases of observation group and 30 cases of control group according to the random number ta- ble method. The efficacy and safety of two groups were compared. Results After each treatment, the local control ratio of the observation group was 63.33%, which was significantly higher than that of 33.33% of the control group. The difference was statistically significant （ X2 = 4. 271, P = 4. 271 ）. The main adverse reaction were decrease of neutrophil and platelet. There was no statistically significant difference in different reaction rate of adverse reaction of two groups （ P 〉 0.05 ）. Conclusion GEMOX regimen for the patients with advanced primary liver cancer can effec- tively improve the clinical curative effect, improve the local control rate. This method does not increase the risk of adverse reaction. This method is worth clinical application.